Drugs / PA83-FhCMB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02239172 | Aug 2014 → May 2015 | anthrax infection | Fraunhofer, Center for Molecular Biotechnology | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA83-FhCMB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02239172 ↗ |
| Modality | Vaccine | “This is the first study demonstrating a plant-derived subunit anthrax vaccine's safety and immunogenicity in healthy adults.” PMID 35153091 ↗ Feb 2022 |
| Route | Intramuscular | “Recipients received three doses of vaccine intramuscularly at 28-day intervals.” PMID 35153091 ↗ Feb 2022 |